Company intelligence / Profile preview
BIO-KER SRL
Pula, Italypubchem.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BIO-KER SRL has multiple biosimilars in development, with their Filgrastim biosimilar in Phase 3 for Neutropenia, and Pegfilgrastim biosimilar and Somatropin biosimilar in Phase 1. They also have Peginterferon beta-1b and BK-0086 (GLP-1R agonist) in pending status.
- Therapeutic areas
- HematologyEndocrinology
- Modalities
- BiosimilarsRecombinant therapeutic proteinsDNA vaccines
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on BIO-KER SRL.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIO-KER SRL.